Clinical Pharmacology of Paliperidone Palmitate A Parenteral Long-Acting Formulation for the Treatment of Schizophrenia

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 2-9

Bentham Science Publishers

Access to resources Recommend Favorite

Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient

By  

ASIA-PACIFIC PSYCHIATRY (ELECTRONIC), Vol. 10, Iss. 1, 2018-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Validation of an economic model of paliperidone palmitate for chronic schizophrenia

By Einarson Thomas R.   Hemels Michiel E. H.  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1267-1274

Informa Healthcare

Access to resources Recommend Favorite

Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE)

By Kozma Chris M.   Slaton Terra   Dirani Riad   Fastenau John   Gopal Srihari   Hough David  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1603-1611

Informa Healthcare

Access to resources Recommend Favorite

Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents

By Kim Eun Young   Chang Sung Man   Shim Joo Cheol   Joo Eun Jeong   Kim Jae Jin   Kim Yong Sik   Ahn Yong Min  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1231-1240

Informa Healthcare

Access to resources Recommend Favorite